Abstract
Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.
Original language | English (US) |
---|---|
Pages (from-to) | 873 |
Number of pages | 1 |
Journal | JAMA - Journal of the American Medical Association |
Volume | 326 |
Issue number | 9 |
DOIs |
|
State | Published - Sep 7 2021 |
ASJC Scopus subject areas
- Medicine(all)